HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Abstract
Antibody-dependent cell cytotoxicity (ADCC) plays a critical role in monoclonal antibody (mAb)-mediated cancer therapy. ADCC, however, has not been directly shown in vivo but inferred from the requirement for IgG Fc receptors (FcγR) in tumor rejection in mice. Here, we investigated the mechanism of action of a Tn antigen-specific chimeric mAb (Chi-Tn), which binds selectively to a wide variety of carcinomas, but not to normal tissues, in both humans and mice. Chi-Tn mAb showed no direct toxicity against carcinomas cell lines in vitro but induced the rejection of a murine breast tumor in 80% to 100% of immunocompetent mice, when associated with cyclophosphamide. Tumor rejection was abolished in Fc receptors-associated γ chain (FcR-γ)-deficient mice, suggesting a role for ADCC. Indeed, tumor cells formed stable conjugates in vivo with FcR-γ chain-expressing macrophages and neutrophils in Chi-Tn mAb-treated but not in control mAb-treated mice. The contact zone between tumor cells and ADCC effectors accumulated actin, FcγR and phospho-tyrosines. The in vivo formed ADCC synapses were organized in multifocal supra-molecular activation clusters. These results show that in vivo ADCC mediated by macrophages and neutrophils during tumor rejection by Chi-Tn mAb involves a novel type of multifocal immune synapse between effectors of innate immunity and tumor cells.
AuthorsPascale Hubert, Adèle Heitzmann, Sophie Viel, André Nicolas, Xavier Sastre-Garau, Pablo Oppezzo, Otto Pritsch, Eduardo Osinaga, Sebastian Amigorena
JournalCancer research (Cancer Res) Vol. 71 Issue 15 Pg. 5134-43 (Aug 01 2011) ISSN: 1538-7445 [Electronic] United States
PMID21697279 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, Tumor-Associated, Carbohydrate
  • Antineoplastic Agents, Alkylating
  • Receptors, IgG
  • Tn antigen
  • Cyclophosphamide
  • Trastuzumab
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm (therapeutic use)
  • Antibody Specificity
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, Tumor-Associated, Carbohydrate (immunology)
  • Antineoplastic Agents, Alkylating (pharmacology, therapeutic use)
  • Breast Neoplasms (immunology, pathology)
  • Cell Line, Tumor (immunology)
  • Combined Modality Therapy
  • Cyclophosphamide (pharmacology, therapeutic use)
  • Cystadenocarcinoma, Serous (immunology, pathology)
  • Female
  • Humans
  • Immunization, Passive
  • Immunological Synapses (immunology, ultrastructure)
  • Macrophages (immunology)
  • Mammary Neoplasms, Experimental (drug therapy, immunology, therapy)
  • Mice
  • Mice, Inbred BALB C
  • Neutrophils (immunology)
  • Ovarian Neoplasms (immunology, pathology)
  • Receptors, IgG (immunology)
  • Trastuzumab
  • Tumor Microenvironment (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: